Contact Us
+61 (0) 419 185 491
+61 (0) 411 816 444
PO Box 636 Bondi Junction
NSW 1355
Australia
admin@lara.org.au
The LAM Australasia Research Alliance (LARA) is dedicated to improving the health prospects of women with LAM in Australia, New Zealand and throughout the region. A disease that affects only women, LAM is rare and often devastating.
ALL DONATIONS TO LARA ARE FULLY TAX DEDUCTIBLE
Your contribution to LARA will go 100% to funding vital medical research to find a cure for LAM.
You can donate to the LAM Australasia Research Alliance by sending us a cheque, using our PayPal facility, or by making a deposit directly to our ANZ Bank account: 012 055 4926 67193.
Please advise us of your donation by sending an email to admin@lara.org.au with your name, address and email address. We will respond with our thanks and a fully tax deductible receipt.
Major Donors
Macquarie Group Foundation
Roth Charitable Foundation
Mr Robert Gavshon
Hollick Wines
Acknowledgements
LARA thanks the professionals who work pro bono for this not-for-profit organisation. We highly recommend the services of:
Ben Higham, Webhead
Karen Riethmuller, KGR Design
Peter Hersh, Loggica Pty Ltd
Peter Kelso
|
BREAKTHROUGH IN LAM RESEARCH
|
BREAKTHROUGH IN LAM RESEARCH (MILES TRIAL FAQs)Research known as the MILES Trial reveals that while being treated with the drug, sirolimus (rapamycin), for one year, patients showed a small but significant improvement in lung function*. However, significant side effects mean that the pros and cons of treatment with sirolimus have to be considered for individual patients.Instrumental in facilitating the MILES Trial, the American LAM Foundation announced the results of this first randomised, controlled study designed to develop a therapy for LAM. Prof Frank McCormack MD, Director of the Pulmonary, Critical Care and Sleep Medicine Division at the University of Cincinnati, was the lead investigator for the study. He is also Scientific Director of The LAM Foundation, which played an integral role in the success of the trial. In addition to recruiting, educating and supporting the women for the trial, The LAM Foundation funded the costs of data monitoring and patient travel. The on-line edition of the New England Journal of Medicine (NEJM) 16.03.2011 includes the trial results and features an editorial paying tribute to the role of The LAM Foundation in advancing research for a very rare disease. Editorial about research into rare diseases Report on MILES Trial The LAM Foundation has expressed appreciation to the LAM patients in the United States, Japan and Canada who were involved in the MILES Trial. “Because of their hope for a treatment and ultimately a cure, they chose to become involved. Trials are not for everyone for a variety of reasons, but for the 111 LAM patients who consented, and the 89 who completed this trial, all LAM patients and their families thank you. Without your courage, a treatment would have been missed. Our gratitude is extended to the generous sponsors who provided the funding. The LAM Foundation would also like to thank Dr McCormack and all the professionals and institutions involved in the MILES Trial.” *FEV(1) Forced Expiratory Volume in 1 second |